These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30938616)

  • 41. A prospective, multi-centre, Veterinary Radiation Therapy Oncology Group study reveals potential efficacy of toceranib phosphate (Palladia) as a primary or adjuvant agent in the treatment of canine nasal carcinoma.
    Ehling TJ; Klein MK; Smith L; Prescott D; Haney S; Looper J; LaDue T; Brawner W; Fidel J; Shiomitsu K; Green E; Saba C; Turek M; Farrelly J
    Vet Comp Oncol; 2022 Mar; 20(1):293-303. PubMed ID: 34655275
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the efficacy and safety of toceranib phosphate in cats with macroscopic mammary adenocarcinoma.
    Del Portillo Miguel I; Blackwood L; Maiques E; Pérez Roger I; Poch Jiménez E; Borrego J
    J Feline Med Surg; 2024 Aug; 26(8):1098612X241256473. PubMed ID: 39212426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Canine anal sac adenocarcinomas: clinical presentation and response to therapy.
    Bennett PF; DeNicola DB; Bonney P; Glickman NW; Knapp DW
    J Vet Intern Med; 2002; 16(1):100-4. PubMed ID: 11822797
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Updated Concepts in Oncologic Surgery: Apocrine Gland Anal Sac Adenocarcinoma and Mast Cell Tumors.
    Mickelson MA
    Vet Clin North Am Small Anim Pract; 2022 Mar; 52(2):549-580. PubMed ID: 35082090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Toxicity and response in cats with neoplasia treated with toceranib phosphate.
    Harper A; Blackwood L
    J Feline Med Surg; 2017 Jun; 19(6):619-623. PubMed ID: 27090289
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib.
    Kovac RL; Ballash G; Fenger J; London C; Warry E
    J Vet Intern Med; 2018 Nov; 32(6):2061-2068. PubMed ID: 30353992
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A relatively high proportion of dogs with small apocrine gland anal sac adenocarcinoma (AGASACA) primary tumours present with locoregional lymph node metastasis.
    Jones AE; Wustefeld-Janssens BG
    Vet Comp Oncol; 2023 Jun; 21(2):327-331. PubMed ID: 36861227
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of abdominal ultrasound and magnetic resonance imaging for detection of abdominal lymphadenopathy in dogs with metastatic apocrine gland adenocarcinoma of the anal sac.
    Anderson CL; MacKay CS; Roberts GD; Fidel J
    Vet Comp Oncol; 2015 Jun; 13(2):98-105. PubMed ID: 23432735
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
    Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
    J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.
    Carlsten KS; London CA; Haney S; Burnett R; Avery AC; Thamm DH
    J Vet Intern Med; 2012; 26(1):135-41. PubMed ID: 22176473
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Retrospective evaluation of toceranib phosphate (Palladia) in cats with oral squamous cell carcinoma.
    Wiles V; Hohenhaus A; Lamb K; Zaidi B; Camps-Palau M; Leibman N
    J Feline Med Surg; 2017 Feb; 19(2):185-193. PubMed ID: 26755491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pancreatic adenocarcinoma treated with surgical resection, toceranib phosphate and firocoxib in a dog: a case report.
    Fuertes-Recuero M; Vázquez-Fernández E; Lizasoain-Sánz G; Arroba-Alonso A; Sánchez-López A; Martínez-de-Merlo E; Suárez-Redondo M; Ortiz-Diez G
    Vet Res Commun; 2024 Jun; 48(3):1921-1927. PubMed ID: 38453822
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcome and clinical, pathological, and immunohistochemical factors associated with prognosis for dogs with early-stage anal sac adenocarcinoma treated with surgery alone: 34 cases (2002-2013).
    Skorupski KA; Alarcón CN; de Lorimier LP; LaDouceur EEB; Rodriguez CO; Rebhun RB
    J Am Vet Med Assoc; 2018 Jul; 253(1):84-91. PubMed ID: 29911942
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
    Remerowski SM; Herrera CL; Donnelly LL
    BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A retrospective study of proteinuria in dogs receiving toceranib phosphate.
    Piscoya SL; Hume KR; Balkman CE
    Can Vet J; 2018 Jun; 59(6):611-616. PubMed ID: 29910474
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Toceranib phosphate in the management of canine insulinoma: A retrospective multicentre study of 30 cases (2009-2019).
    Sheppard-Olivares S; Bello NM; Johannes CM; Hocker SE; Biller B; Husbands B; Snyder E; McMillan M; McKee T; Wouda RM
    Vet Rec Open; 2022 Dec; 9(1):e27. PubMed ID: 35079406
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018).
    Sheppard-Olivares S; Bello NM; Wood E; Szivek A; Biller B; Hocker S; Wouda RM
    Vet Comp Oncol; 2020 Dec; 18(4):519-527. PubMed ID: 32012432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
    Mitchell L; Thamm DH; Biller BJ
    J Vet Intern Med; 2012; 26(2):355-62. PubMed ID: 22303814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
    Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
    BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.